SmithKline Beckman Corp. announced that it will...
- Share via
SmithKline Beckman Corp. announced that it will invest $49 million in a partnership with Nova Pharmaceutical Corp. to develop new therapies for the treatment of central nervous system diseases. Philadelphia-based SmithKline also agreed, in a separate action, to collaborate with Nova in the development, manufacture and marketing of Nova’s bradykinin antagonist drugs, which Nova is testing as a treatment for common cold symptoms.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
